What is HC Wainwright’s Estimate for PepGen FY2025 Earnings?

PepGen Inc. (NASDAQ:PEPG) – Equities research analysts at HC Wainwright lowered their FY2025 earnings per share estimates for shares of PepGen in a research note issued to investors on Monday, February 24th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of ($2.96) for the year, down from their prior estimate of ($2.42). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for PepGen’s FY2026 earnings at ($2.54) EPS, FY2027 earnings at ($1.99) EPS, FY2028 earnings at ($1.26) EPS and FY2029 earnings at ($0.31) EPS.

PepGen (NASDAQ:PEPG) last released its earnings results on Monday, February 24th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.13.

Several other brokerages have also weighed in on PEPG. Bank of America lowered PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 target price on the stock. in a research report on Monday, December 16th. Wedbush cut their price objective on PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a report on Friday, November 8th.

PepGen Stock Up 58.8 %

Shares of PEPG opened at $2.43 on Thursday. PepGen has a fifty-two week low of $1.16 and a fifty-two week high of $19.30. The company’s fifty day moving average is $2.38 and its two-hundred day moving average is $5.72. The firm has a market cap of $79.21 million, a PE ratio of -0.82 and a beta of 1.53.

Institutional Investors Weigh In On PepGen

Large investors have recently made changes to their positions in the business. RTW Investments LP acquired a new position in shares of PepGen during the fourth quarter worth about $12,102,000. Janus Henderson Group PLC grew its stake in shares of PepGen by 331.2% in the third quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock worth $20,012,000 after purchasing an additional 1,794,641 shares in the last quarter. Millennium Management LLC increased its holdings in shares of PepGen by 1,033.2% during the fourth quarter. Millennium Management LLC now owns 156,636 shares of the company’s stock valued at $594,000 after purchasing an additional 142,814 shares during the period. Suvretta Capital Management LLC raised its stake in shares of PepGen by 9.2% during the third quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock valued at $14,201,000 after purchasing an additional 140,000 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in PepGen in the fourth quarter worth about $516,000. Institutional investors and hedge funds own 58.01% of the company’s stock.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.